Amryt Pharma Share Discussion Threads

[alphabravo321] 14/8/2020 07:47

Excellent presentation from Rory

[bazworth] 13/8/2020 22:07

I only had sound and PowerPoint slides. Well worth listening

[bageo] 13/8/2020 21:41

Great, thanks will watch this.

[bageo] 13/8/2020 21:21

where is the live conference available, thanks

[bazworth] 13/8/2020 20:40

He was quite amazing! I’m incredibly happy to hold to see how the next couple of years or so develop.

[digadee] 13/8/2020 20:31

No disrepect to joe but rory does do a cracking job with relaying information

[bazworth] 13/8/2020 20:11

Just listening to the live conference, fascinating!!

[papillon] 10/8/2020 22:47

Well, Punter6, the AMYT BoD say they are switching their big share holdings to Nasdaq, including Joe Wiley and the Chairman. I wont be switching my small shareholding. It depends on your longer term view of the £ vs $ exchange rate and whether your broker will allow you to switch and whether he allows you to trade on Nasdaq in $'s.

[ultrasharp] 10/8/2020 21:09

Currently US$11.75 on Nasdaq. Dividing by 5 and then 1.307 (current exchange rate) gives £1.80. So very slightly lower on Nasdaq.

ATB papillon

[punter6] 10/8/2020 14:48

Are we better off holding stock,as the Yanks say,on NASDAQ rather than shares on AIM..?

Is it possible to switch?

[diamondstar1] 10/8/2020 14:44

Nasdaq website shows Amryt share price up 6.78% to $12.40 this morning.

[delta0091] 10/8/2020 11:34

Amryt Pharma (AMYT)

Boasting a market cap of $364.9 million, Amryt Pharma develops therapies that could potentially improve the lives of patients with rare, debilitating conditions. With operational tailwinds set to propel it forward, it’s no wonder Canaccord gave it a thumbs up.

5-star analyst Michelle Gilson points to AMYT’s expanding base business as being a key component of her bullish thesis. She highlights that lomitapide, which is approved in the U.S. and EU for homozygous familial hypercholesterolemia (HoFH), drove revenues of $45 million in Q1 2020 and metreleptinm, its asset for generalized lipodystrophy (GL) and partial lipodystrophy (PL), generated $157 million in 2019. It should also be noted that AMYT achieved adjusted EBITDA profitability and cash flow positivity in Q1, demonstrating the build-out of a more efficient infrastructure following the acquisition of Aegerion has been effective, in the analyst’s opinion.

“With a strengthened B/S to support the new business model (reduced debt burden, increased cash with equity raise), the Amryt team has been able to focus on and invest in the EU launch of metreleptin and re-establishment of medical affairs to reduce unnecessary discontinuations, which should support continued organic growth,” Gilson explained.

In addition, the company has placed a significant focus on expanding the labels for these two drugs. Gilson told clients, “Studies are underway/planned for metreleptin in PL (U.S.), lomitapide in familial chylomicronemia syndrome (FCS), and lomitapide in pediatric HoFH... If successful, these indications could double the market opportunity in the US for metreleptin and WW for lomitapide.”

When it comes to Filsuvez (AP101), its topical therapeutic designed for use in epidermolysis bullosa (EB), Gilson also sees a major opportunity. Filsuvez has already shown that it can speed up healing times in partial thickness wounds, so the analyst has high hopes ahead of the Phase 3 data readout, which is slated for late Q3 or early Q4. As such, this event could be an important near-term catalyst. If that wasn’t enough, the company’s pipeline includes a polymer-based, topical gene therapy platform, with the lead candidate, AP103, for dystrophic EB expected to enter clinical development in 2H21.

Based on all of the above, Gilson rates AMYT a Buy rating, along with a $40 price target. This figure implies shares could soar 269% in the next year. (To watch Gilson’s track record, click here)

AMYT has stayed relatively under-the-radar, with its Moderate Buy consensus rating breaking down into 2 Buys and no Holds or Sells. At $42.50, the average price target indicates upside potential in the shape of a whopping 287%. (See AMYT stock analysis on TipRanks)

[digadee] 10/8/2020 08:38

hxxps://www.nasdaq.com/articles/these-2-small-cap-stocks-could-see-50-plus-gains-says-canaccord-2020-08-03

[bazworth] 09/8/2020 22:00

hxxps://www.independent.ie/business/irish/amryt-pharma-raises-2020-outlook-citing-sales-growth-and-drug-trials-39430001.html

[alphabravo321] 09/8/2020 13:52

Irish Independent had an article with Wiley this week where he said he is hopeful for AP 101 results by October

[bazworth] 09/8/2020 13:38

From the snippets I have read, AP101 could have a significant impact if approved etc.

Sales force in place so we could be in for quite a ride!!

Forever hopeful...

[sidam] 09/8/2020 12:22

Did anyone listen to the results presentation. I thought it was OK. Sales in H 1 were higher than they would normally expect for exceptional reasons so expected revenues of 170 to 175m are acceptable. Some of the projected savings will not flow through until next year so costs should fall. Revenues look to be higher next year and could show good growth if current portfolio could be used for a wider category of patients.

And the big question on AP 101 could be answered in two months.

So overall quite satisfactory. Any comments?

[bazworth] 09/8/2020 11:35

Very promising!

Wonder when we will hear of the results?

Cheers

[papillon] 07/8/2020 00:29

A very large trade of 100k ADS's (= 500k AMYT shares) on Nasdaq @ US$11.30 timed @ 14:12 ET. A sell?

Total volume on Nasdaq = 153,667 ADS's

[diamondstar1] 06/8/2020 22:04

Nice volume & nice surge on Nasdaq at the end!

[digadee] 06/8/2020 20:37

Nice bit of volume on nasdaq